Office Action Predictor
Application No. 17/823,805

SINGLE-STRAND BINDING PROTEIN

Non-Final OA §112
Filed
Aug 31, 2022
Examiner
WOOLWINE, SAMUEL C
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Universitetet I Tromsø - Norges Arktiske Universitet
OA Round
2 (Non-Final)
61%
Grant Probability
Moderate
2-3
OA Rounds
3y 9m
To Grant
70%
With Interview

Examiner Intelligence

61%
Career Allow Rate
514 granted / 842 resolved
Without
With
+9.0%
Interview Lift
avg trend
3y 9m
Avg Prosecution
53 pending
895
Total Applications
career history

Statute-Specific Performance

§101
5.3%
-34.7% vs TC avg
§103
36.2%
-3.8% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
28.2%
-11.8% vs TC avg
Black line = Tech Center average estimate • Based on career data

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment Applicant’s reply of 08/06/2025 is acknowledged. The amendment overcomes all objections/rejections in the Office action mailed 05/21/2025. However, after additional review, new issues have been identified resulting in new rejections below. This Office action is therefore made NON-FINAL. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims are recited in the format of “use” claims. See MPEP 2173.05(q). In essence, the claims appear to attempt to claim a process without setting forth any steps involved in the process, and are therefore indefinite. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 2 and 10 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 2 and 10 each recite two options. The first option in each case does not further limit the claim relative to the claim from which it depends, as this option is already recited in the parent claim (claims 1 and 9). Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claims 4 and 12 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 4 and 12 depend from claims 3 and 11, respectively. Claims 3 and 11 each require the replacement amino acid to carry a positive charge on its side chain at pH 7. Claims 4 and 12 list (among the amino acid options) tyrosine, asparagine and glutamine. None of these has a positively charged side chain at pH 7. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAMUEL C WOOLWINE whose telephone number is (571)272-1144. The examiner can normally be reached 9am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, GARY BENZION can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAMUEL C WOOLWINE/Primary Examiner, Art Unit 1681
Read full office action

Prosecution Timeline

Aug 31, 2022
Application Filed
May 17, 2025
Non-Final Rejection — §112
Aug 06, 2025
Response Filed
Sep 29, 2025
Non-Final Rejection — §112
Mar 30, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology. Study what changed to get past this examiner.

Patent 12595462
HIGH THROUGHPUT GENETIC BARCODING AND ANALYSIS METHODS
2y 5m to grant Granted Apr 07, 2026
Patent 12584167
METHOD FOR AMPLIFYING NUCLEOTIDE SEQUENCE AND SEQUENCE DETERMINATION
2y 5m to grant Granted Mar 24, 2026
Patent 12545951
SIMPLIFIED POLYNUCLEOTIDE SEQUENCE DETECTION METHOD
2y 5m to grant Granted Feb 10, 2026
Patent 12534569
FLOW CELLS
2y 5m to grant Granted Jan 27, 2026
Patent 12529097
DIGITAL ANALYTE ANALYSIS
2y 5m to grant Granted Jan 20, 2026

AI Strategy Recommendation

Click below to generate an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
61%
Grant Probability
70%
With Interview (+9.0%)
3y 9m
Median Time to Grant
Moderate
PTA Risk
Based on 842 resolved cases by this examiner